PDL BIOPHARMA, INC.
REDWOOD CITY, CA US
|PDL BIOPHARMA, INC. Patent applications|
|Patent application number||Title||Published|
|20130338038||METHOD OF SCREENING COMPLEX PROTEIN LIBRARIES TO IDENTIFY ALTERED PROPERTIES - The invention provides methods of making designed and constructed protein (e.g., antibody) libraries and libraries resulting from the same.||12-19-2013|
|20130338017||METHODS OF SCREENING COMPLEX PROTEIN LIBRARIES TO IDENTIFY ALTERED PROPERTIES - The invention provides methods of making designed and constructed protein (e.g., antibody) libraries and libraries resulting from the same.||12-19-2013|
|20110008883||MAMMALIAN CELL-BASED IMMUNOGLOBULIN DISPLAY LIBRARIES - Disclosed are mammalian cell surface display vectors for isolating and/or characterizing immunoglobulins and various uses thereof.||01-13-2011|
|20090136950||IMMUNOGLOBULIN DISPLAY VECTORS - Disclosed are mammalian expression vectors for expressing simultaneous expression of immunoglobulins as both a secreted and cell surface bound form.||05-28-2009|
|20090111126||MAMMALIAN CELL-BASED IMMUNOGLOBULIN DISPLAY LIBRARIES - Disclosed are mammalian cell surface display vectors for isolating and/or characterizing immunoglobulins and various uses thereof.||04-30-2009|
|20090074762||THERAPEUTIC USE OF ANTI-TWEAK RECEPTOR ANTIBODIES - Compositions and methods for treating solid tumors are provided herein.||03-19-2009|
|20080287657||Alteration of Fc-fusion protein serum half-lives by mutagenesis - The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.||11-20-2008|
|20080260740||Anti-LFL2 Antibodies for the Diagnosis, Prognosis and Treatment of Cancer - Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.||10-23-2008|
|20080260730||Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies - The present invention provides a method of treating autoimmune diseases. In particular, it provides a method for the treatment of Crohn's disease or psoriasis comprising administering to a subject in need thereof a therapeutically effective amount of an antibody against interferon γ.||10-23-2008|
|20080226632||AMPHIREGULIN ANTIBODIES AND THEIR USE TO TREAT CANCER AND PSORIASIS - The present invention is directed to anti-AR antibodies, preferably humanized monoclonal antibodies having the amino acid sequences disclosed herein. The present invention includes a pharmaceutical composition comprising such antibodies. The present invention includes a method of inhibiting cancer cell growth comprising administering such antibodies into a subject. The present invention also provides a method of treating cancer or psoriasis in a subject in need of such a treatment by administering such antibodies to said subject in a pharmaceutically effective amount.||09-18-2008|
Patent applications by PDL BIOPHARMA, INC.